Printer Friendly

Precocious puberty treated by hormone.

WASHINGTON, D.C. A synthetic hormone called histrelin acetate was recently approved to treat central, or unexplained, precocious puberty, in which young children develop the sexual characteristics of adolescents.

About 6,000 American children have this condition, with 2,000 new cases diagnosed each year. Histrelin acetate was developed as an orphan product by Ortho Pharmaceuticals of Raritan, N.J., and will be marketed under the brand name Supprelin. Orphan status provides incentives for companies to develop products for use in conditions that afflict fewer than 200,000 people.

In idiopathic central precocious puberty, the most common form of precocious puberty, sexual development occurs without known cause before age 8 in girls and age 9 in boys. (In other forms, factors such as injury may be involved.) These children at first grow faster than normal, but their bones mature only to a certain state, after which no growth occurs, often with failure to reach full adult height. They also tend to have emotional problems commonly associated with adolescence. Their intellectual development, however, matches their actual age.

Supprelin is given at home by a parent as a daily injection, similar to the way insulin is given to juvenile diabetics. The drug causes hormone levels to return to normal, development of sexual characteristics to stop, and skeletal maturation to decelerate. Full adult height then becomes attainable. Physician labeling and a patient information brochure stress the need to give the injection at the same time each day. Directions warns that puberty will not be controlled if the drug is not administered consistently.

Injections can be stopped when a child reaches the appropriate age for onset of puberty.

In clinical trials involving 183 children, the most frequent adverse effects associated with the drug, occurring in 5 percent of patients, were skin reactions at the injection site such as redness, swelling, and itching. In 22% of the girls, light vaginal bleeding occurred during the first month. Other infrequent effects included headache, nausea, and vomiting.
COPYRIGHT 1992 Vegetus Publications
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:histrelin acetate
Publication:Nutrition Health Review
Date:Mar 22, 1992
Previous Article:Burns: a guide to self-treatment.
Next Article:Television and teen suicide: more than a coincidence?

Related Articles
Premature puberty: is early sexual development the price of pollution?
DDT Exposure Linked to Early Sexual Development In Immigrants to Belgium.
BODY TALK: Growing up too quickly.. We investigate why more and more children are going through puberty shockingly early...
The Mag: REAL LIFE: Girl who started puberty aged 3.
Abnormalities in Puberty: Scientific and Clinical Advances.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters